TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02730923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request.
Study: NCT03320538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi
Description: Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi
Description: Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
Study: NCT05246124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zumba dance exercise
Description: The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
Study: NCT03320538

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
Study: NCT02215187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Training (PST)
Description: Training in problem-solving skills to be applied to military caregiver problems.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control
Description: Social contact control (health education/no skill training)
Study: NCT03320538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
Study: NCT01345851

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Description: Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo hypofractionated RT
Study: NCT01309867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Toric Lens
Description: Bausch \& Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision Toric Lens
Description: Currently marked Bausch \& Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
Study: NCT02540772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological treatment
Description: Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
Study: NCT04198519

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.
Study: NCT03202745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Consequences Letter
Description: This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescriber Consequences Letter
Description: This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
Study: NCT03230513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Epley Manoeuvre
Description: The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brandt-Daroff Exercise
Description: The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
Study: NCT01431261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and training
Description: Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain management
Description: Educational sessions in pain management 4 times
Study: NCT00592670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
Study: NCT01095068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Study: NCT02657187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inbody
Description: Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
Study: NCT01584843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: IM injection of Botulinum Toxin Type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: IM injection of Botulinum Toxin Type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: IM injection of Botulinum Toxin Type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: IM injection of Botulinum Toxin Type A
Study: NCT05244395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duchenne Muscular Dystrophy Gait Assessment Scale
Description: a special gait assessment scale for Duchenne Muscular Dystrophy patients
Study: NCT01620619

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Bankart Repair alone
Description: Usual arthroscopic Bankart repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of rotator interval
Description: Usual arthroscopic Bankart repair plus rotator cuff interval closure
Study: NCT03347422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sutimlimab (BIVV009)
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sutimlimab (BIVV009)
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
Study: NCT02538536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI4050
Study: NCT02657187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inbody
Description: Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inbody
Description: Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inbody
Description: Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
Study: NCT00331032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% w/w SPL7013 Gel
Description: Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
Study: NCT03235882

Intervention type: DIAGNOSTIC_TEST
Intervention: LS-ratio
Description: Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
Study: NCT01930604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox (onabotulinumtoxinA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox (onabotulinumtoxinA)
Study: NCT02657187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
Study: NCT01930604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox (onabotulinumtoxinA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroBloc/Myobloc (rimabotulinumtoxinB)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroBloc/Myobloc (rimabotulinumtoxinB)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (placebo)
Study: NCT01930604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (placebo)
Study: NCT04346147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib tablets
Description: Imatinib 400 mg QD oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet
Description: Baricitinib 4 mg QD oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive tratment
Description: Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
Study: NCT03495141

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervision/Coaching
Description: Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervision/Coaching
Description: Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
Study: NCT04557306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBT101 cells, every 2 weeks
Description: CBT101 cells, every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBT101 cells, every 4 weeks
Description: CBT101 cells, every 4 weeks
Study: NCT02632513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)
Description: In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
Study: NCT03034655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDP
Description: Vestibular rehabilitation using CDP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDP
Description: Vestibular rehabilitation using CDP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile posturography
Description: Vestibular rehabilitation using mobile posturography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile posturography
Description: Vestibular rehabilitation using mobile posturography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 sessions
Description: Vestibular rehabilitation, ten sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 sessions
Description: Vestibular rehabilitation, ten sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 sessions
Description: Vestibular rehabilitation, five sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 sessions
Description: Vestibular rehabilitation, five sessions
Study: NCT01858831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil HCL
Description: Atovaquone/proguanil HCL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atovaquone
Description: Atovaquone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atovaquone
Description: Atovaquone
Study: NCT01014273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Study: NCT04164459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalost S
Description: One drop one times a day in study eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: One drop one times a day in study eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taflotan-S
Description: One drop one times a day in study eye
Study: NCT03819829

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample
Study: NCT03966898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390 Tablets
Description: SHR6390 Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole or Anastrozole Tablets
Description: Letrozole or Anastrozole Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole or Anastrozole Tablets
Description: Letrozole or Anastrozole Tablets
Study: NCT03501264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Game
Description: LGBTQ Bullying game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LGBTQ Resources
Description: This group receives LGBTQ Resources
Study: NCT05555719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Protraction Appliance
Description: Mandibular Protraction Appliance was installed on fixed orthodontic appliance
Study: NCT01176877

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Scripted lecture (educational information talk)
Description: This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
Study: NCT01918241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim,30mcg/kg
Description: Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim, 60mcg/kg
Description: Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim, 100mcg/kg
Description: Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim, 5mcg/kg
Description: At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
Study: NCT00132301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Chemotherapy agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: steroid in combination with chemotherapy agent
Study: NCT03388541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
Study: NCT04609605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: speckle tracking echocardiography
Description: speckle tracking echocardiography of right ventricle
Study: NCT02339805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: next generation sequencing
Description: DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)
Description: tumor Assessment tool during the study
Study: NCT00142792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES device with EMG-triggered and Cyclic capabilities
Description: All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES device with EMG-triggered and Cyclic capabilities
Description: All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES device with EMG-triggered and Cyclic capabilities
Description: All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
Study: NCT01763333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706 Placebo
Description: Placebo to BI 1026706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: different dose formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: different dose formulations
Study: NCT02112539

Intervention type: OTHER
Intervention: platelet aggregation measurement
Study: NCT02596139

Intervention type: OTHER
Intervention: No Interventions